BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Spronsen DJ, de Weijer KJM, Mulders PFA, De Mulder PHM. Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anti-Cancer Drugs 2005;16:709-17. [DOI: 10.1097/01.cad.0000167901.58877.a3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Lin PP, Mirza AN, Lewis VO, Cannon CP, Tannir NM, Yasko AW. Patient Survival After Surgery for Osseous Metastases from Renal Cell Carcinoma*: . The Journal of Bone and Joint Surgery-American Volume 2007;89:1794-801. [DOI: 10.2106/00004623-200708000-00018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
2 Jin P, Wang J, Liu Y. Downregulation of a novel long non-coding RNA, LOC389332, is associated with poor prognosis and tumor progression in clear cell renal cell carcinoma. Exp Ther Med 2017;13:1137-42. [PMID: 28450954 DOI: 10.3892/etm.2017.4080] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
3 Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 2007;29:1338-53. [PMID: 17825686 DOI: 10.1016/j.clinthera.2007.07.022] [Cited by in Crossref: 113] [Cited by in F6Publishing: 105] [Article Influence: 7.5] [Reference Citation Analysis]
4 Hao B, Peng X, Bi B, Yu M, Sang C, Chen Z. Preoperative serum high-density lipoprotein cholesterol as a predictor of poor survival in patients with clear cell renal cell cancer. Int J Biol Markers 2019;34:168-75. [DOI: 10.1177/1724600819831404] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Chen S, Wang L, Yao X, Chen H, Xu C, Tong L, Shah A, Huang T, Chen G, Chen J, Liu T, Li X, Zheng J, Li L. miR-195-5p is critical in REGγ-mediated regulation of wnt/β-catenin pathway in renal cell carcinoma. Oncotarget 2017;8:63986-4000. [DOI: 10.18632/oncotarget.19256] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
6 Chauhan A, Semwal DK, Mishra SP, Goyal S, Marathe R, Semwal RB. Combination of mTOR and MAPK Inhibitors-A Potential Way to Treat Renal Cell Carcinoma. Med Sci (Basel) 2016;4:E16. [PMID: 29083380 DOI: 10.3390/medsci4040016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Tang SW, Lin JY. Full-Length Enrich c-DNA Libraries-Clear Cell-Renal Cell Carcinoma. J Oncol 2012;2012:680796. [PMID: 22545051 DOI: 10.1155/2012/680796] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
8 Wang SC, Tang SW, Lam SH, Wang CC, Liu YH, Lin HY, Lee SS, Lin JY. Aqueous Extract of Paeonia suffruticosa Inhibits Migration and Metastasis of Renal Cell Carcinoma Cells via Suppressing VEGFR-3 Pathway. Evid Based Complement Alternat Med 2012;2012:409823. [PMID: 22454663 DOI: 10.1155/2012/409823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
9 Wendt K, Wilk E, Buyny S, Schmidt RE, Jacobs R. Interleukin-21 differentially affects human natural killer cell subsets. Immunology. 2007;122:486-495. [PMID: 17635612 DOI: 10.1111/j.1365-2567.2007.02675.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
10 Ranieri E, Gigante M, Storkus WJ, Gesualdo L. Translational mini-review series on vaccines: Dendritic cell-based vaccines in renal cancer. Clin Exp Immunol 2007;147:395-400. [PMID: 17302887 DOI: 10.1111/j.1365-2249.2006.03305.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
11 Liu Y, Qian J, Li X, Chen W, Xu A, Zhao K, Hua Y, Huang Z, Zhang J, Liang C, Su S, Li P, Shao P, Li J, Qin C, Wang Z. Long noncoding RNA BX357664 regulates cell proliferation and epithelial-to-mesenchymal transition via inhibition of TGF-β1/p38/HSP27 signaling in renal cell carcinoma. Oncotarget 2016;7:81410-22. [PMID: 27806310 DOI: 10.18632/oncotarget.12937] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
12 Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy. 2007;27:1125-1144. [PMID: 17655513 DOI: 10.1592/phco.27.8.1125] [Cited by in Crossref: 74] [Cited by in F6Publishing: 63] [Article Influence: 4.9] [Reference Citation Analysis]
13 Strube A, Stepina E, Mumberg D, Scholz A, Hauff P, Käkönen SM. Characterization of a new renal cell carcinoma bone metastasis mouse model. Clin Exp Metastasis 2010;27:319-30. [PMID: 20443133 DOI: 10.1007/s10585-010-9329-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
14 Tan Q, Wang W, Long Y, Chen G. Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis. Exp Ther Med 2015;9:2275-80. [PMID: 26136973 DOI: 10.3892/etm.2015.2427] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Liu Y, Zhang M, Qian J, Bao M, Meng X, Zhang S, Zhang L, Zhao R, Li S, Cao Q, Li P, Ju X, Lu Q, Li J, Shao P, Qin C, Yin C. miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells. DNA Cell Biol 2015;34:429-36. [PMID: 25811077 DOI: 10.1089/dna.2014.2629] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 6.6] [Reference Citation Analysis]
16 Doğan A, Demirci S, Telci D, Canikyan S, Kongur M, Dede B, Şahin F. Anticancer activity of Schiff base-Poloxamer P85 combination against kidney cancer. Int Urol Nephrol 2018;50:247-55. [PMID: 29288416 DOI: 10.1007/s11255-017-1782-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
17 Qin C, Han Z, Qian J, Bao M, Li P, Ju X, Zhang S, Zhang L, Li S, Cao Q, Lu Q, Li J, Shao P, Meng X, Zhang W, Yin C. Expression pattern of long non-coding RNAs in renal cell carcinoma revealed by microarray. PLoS One 2014;9:e99372. [PMID: 24905231 DOI: 10.1371/journal.pone.0099372] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
18 Chen Y, Liu J, Lv P, Gao J, Wang M, Wang Y. IL-6 is involved in malignancy and doxorubicin sensitivity of renal carcinoma cells. Cell Adh Migr 2018;12:28-36. [PMID: 28328292 DOI: 10.1080/19336918.2017.1307482] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
19 Hao B, Cui L, Gu Y, Zhang B, Wang M, Zhou H, Xu R, He X. WITHDRAWN: MicroRNA-99a Suppresses Proliferation, Migration, Invasion and Induces G1-phase Cell Cycle Arrest via Targeting Insulin-like Growth Factor 1 Receptor Pathway in Renal Cell Carcinoma 786-0 and OS-RC-2 Cells. Urology 2017:S0090-4295(17)30015-8. [PMID: 28088554 DOI: 10.1016/j.urology.2017.01.003] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
20 Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AW. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am. 2007;89:1794-1801. [PMID: 17671020 DOI: 10.2106/jbjs.f.00603] [Cited by in Crossref: 93] [Cited by in F6Publishing: 44] [Article Influence: 6.2] [Reference Citation Analysis]
21 Toma CD, Dominkus M, Nedelcu T, Abdolvahab F, Assadian O, Krepler P, Kotz R. Metastatic bone disease: a 36-year single centre trend-analysis of patients admitted to a tertiary orthopaedic surgical department. J Surg Oncol 2007;96:404-10. [PMID: 17541968 DOI: 10.1002/jso.20787] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
22 McKeage K, Wagstaff AJ. Sorafenib: in advanced renal cancer. Drugs 2007;67:475-83; discussion 484-5. [PMID: 17335301 DOI: 10.2165/00003495-200767030-00009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
23 Wang L, Ma L, Wang X, Li B, Guo S, Qiao Q. Therapeutic effects and associated adverse events of first-line treatments of advanced renal cell carcinoma (RCC): a meta-analysis. Int Urol Nephrol 2015;47:617-24. [PMID: 25686740 DOI: 10.1007/s11255-015-0932-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
24 Cui L, Zhou H, Zhao H, Zhou Y, Xu R, Xu X, Zheng L, Xue Z, Xia W, Zhang B, Ding T, Cao Y, Tian Z, Shi Q, He X. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. BMC Cancer 2012;12:546. [PMID: 23173671 DOI: 10.1186/1471-2407-12-546] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 6.7] [Reference Citation Analysis]
25 Haferkamp A, Rohde D, Müller SC, Rübben H, Hohenfellner M. [Renal cell carcinoma]. Urologe A 2006;45 Suppl 4:74-84. [PMID: 16900370 DOI: 10.1007/s00120-006-1136-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Zhang B, Chu W, Wen F, Zhang L, Sun L, Hu B, Wang J, Su Q, Mei Y, Cao J, Zheng J, Mou X, Dong H, Lin X, Wang N, Ji H. Dysregulation of Long Non-coding RNAs and mRNAs in Plasma of Clear Cell Renal Cell Carcinoma Patients Using Microarray and Bioinformatic Analysis. Front Oncol 2020;10:559730. [PMID: 33330027 DOI: 10.3389/fonc.2020.559730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061-1068. [PMID: 20100962 DOI: 10.1200/jco.2009.23.9764] [Cited by in Crossref: 1701] [Cited by in F6Publishing: 749] [Article Influence: 141.8] [Reference Citation Analysis]
28 Chen J, Ruan X, Wang S, Zhang B, Liu B, Sun Z, Liu Q. Antitumor effect and biological pathways of a recombinant adeno-associated virus as a human renal cell carcinoma suppressor. Tumour Biol 2014;35:10993-1003. [PMID: 25091575 DOI: 10.1007/s13277-014-2393-z] [Reference Citation Analysis]
29 Sartini D, Muzzonigro G, Milanese G, Pierella F, Rossi V, Emanuelli M. Identification of Nicotinamide N-Methyltransferase as a Novel Tumor Marker for Renal Clear Cell Carcinoma. Journal of Urology 2006;176:2248-54. [DOI: 10.1016/j.juro.2006.07.046] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 3.2] [Reference Citation Analysis]
30 Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28:1779-1802. [PMID: 17212999 DOI: 10.1016/j.clinthera.2006.11.015] [Cited by in Crossref: 343] [Cited by in F6Publishing: 291] [Article Influence: 22.9] [Reference Citation Analysis]
31 Ren Y, Wang X, Lou Z, Huang S, Zhuang H, Wang Y, Weng G, Wang P. Induction of cell cycle arrest by increasing GTP‑RhoA levels via Taxol‑induced microtubule polymerization in renal cell carcinoma. Mol Med Rep 2017;15:4273-9. [PMID: 28487984 DOI: 10.3892/mmr.2017.6543] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
32 Zhang Y, Lan X, Wang Y, Liu C, Cui T. CRNDE mediates the viability and epithelial-mesenchymal transition of renal cell carcinoma via miR-136-5p. J Recept Signal Transduct Res 2021;41:234-44. [PMID: 32808846 DOI: 10.1080/10799893.2020.1805629] [Reference Citation Analysis]
33 Yang S, de Souza P, Alemao E, Purvis J. Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. Br J Cancer 2010;102:1456-60. [PMID: 20461090 DOI: 10.1038/sj.bjc.6605647] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
34 Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, Völler MC, De Weijer K, Mulders PF, Oosterwijk E. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J Immunother 2007;30:116-22. [PMID: 17198090 DOI: 10.1097/01.cji.0000211318.22902.ec] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
35 Reddy GK, Tyagi P. Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA; June 2-6, 2006. Clin Genitourin Cancer 2006;5:18-22. [PMID: 16859574 DOI: 10.1016/s1558-7673(11)70159-8] [Reference Citation Analysis]